Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by vikingguyon May 24, 2017 6:15pm
208 Views
Post# 26279935

RE:RE:RE:RE:RE:RE:Corrected timing of FDA acceptance of Ibalizumab application

RE:RE:RE:RE:RE:RE:Corrected timing of FDA acceptance of Ibalizumab applicationManagement can make the excuse that they are concentrating all of their efforts on a succesfull IBA launch and preparing the company for big growth....everyone will be fine with that for now. It is up to analysts, institutions etc. to get our story out there and find fresh money. This will look after itself when we get approval, but you better believe that the big pump is coming from those that have been quietly accumulating over the last few months. There will be some celebratory days on this board when we go up by more than a dollar without news I bet.

Today was a nice green day, finishing at the high of day taking out that small wall at 6.55 in the last 2 min.....green tomorrow i bet. 
Bullboard Posts